Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

IMPORTANCE: Poly(adenosine diphosphate–ribose) polymerase inhibitor and anti–programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the clinical activity (primary) and safety (secon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Vinayak, Shaveta, Tolaney, Sara M., Schwartzberg, Lee, Mita, Monica, McCann, Georgia, Tan, Antoinette R., Wahner-Hendrickson, Andrea E., Forero, Andres, Anders, Carey, Wulf, Gerburg M., Dillon, Patrick, Lynce, Filipa, Zarwan, Corrine, Erban, John K., Zhou, Yinghui, Buerstatte, Nathan, Graham, Julie R., Arora, Sujata, Dezube, Bruce J., Telli, Melinda L.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567845/
https://ncbi.nlm.nih.gov/pubmed/31194225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1029
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars